<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunophenotyping of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) in children using three-color flow cytometry was carried out at Chulalongkorn Hospital, Bangkok, Thailand </plain></SENT>
<SENT sid="1" pm="."><plain>Of 38 patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 65.8% were identified as <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">common ALL</z:e>, 15.8% were <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, and 18.4% were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Of these 38 cases, there were 4 cases of infantile <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Relapsed cases of <z:hpo ids='HP_0001909'>leukemia</z:hpo> were found most in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> up to 3 out of 6 cases and to a lesser extent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (1 of 7 cases) and <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">c-ALL</z:e> (1 of 25 cases) </plain></SENT>
<SENT sid="4" pm="."><plain>Our data showed the CD markers expression for <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">common ALL</z:e> (<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">c-ALL</z:e>) were CD19+/10+ (100%), CD20+ (24%), CD22+ (100%), HLA-DR+ (70.1%), and CD34+ (58.8%) </plain></SENT>
<SENT sid="5" pm="."><plain>CD markers expression for <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> were CD19+ (100%), CD20+ (33.3%), CD22+ (80%), and HLA-DR+ (80%) </plain></SENT>
<SENT sid="6" pm="."><plain>CD markers expression for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> were CD3+ (42.9%), CD5+ (100%), CD7+ (85.7%) </plain></SENT>
<SENT sid="7" pm="."><plain>Myeloid aberrant expressions were found in <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">c-ALL</z:e> (25-37.5%), <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> (20%), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (14.3%) </plain></SENT>
<SENT sid="8" pm="."><plain>The significance of the aberration is discussed </plain></SENT>
<SENT sid="9" pm="."><plain>The immunophenotyping classification of ALL as <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">c-ALL</z:e>, <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> is useful in prognosis and treatment </plain></SENT>
</text></document>